# MAXALT-MLT — FDA application NDA020865

Informational only - not investment advice.

Application NDA020865 · type NDA · FDA status: approved · original approval 1998-06-29

Listed sponsor: ORGANON · [OGN company profile](/company/OGN/) · exact_unique

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

## FDA application facts

| Product | FDA-listed trade name | Active ingredient | Dosage form | Route | Strength | Marketing status | TE code | RLD |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 001 | MAXALT-MLT | RIZATRIPTAN BENZOATE | TABLET, ORALLY DISINTEGRATING | ORAL | EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | Discontinued | not listed | Yes |
| 002 | MAXALT-MLT | RIZATRIPTAN BENZOATE | TABLET, ORALLY DISINTEGRATING | ORAL | EQ 10MG BASE | Prescription | AB | Yes |

## Orange Book patent and exclusivity listings

No Orange Book patent or exclusivity listings joined to this application.

Patent and exclusivity dates are regulatory listings from the FDA Orange Book; no relationship to revenue or future sales is stated or implied.

## Compound cross-links

- RIZATRIPTAN BENZOATE · UNII WR978S7QHH · [lmmol compound JPRXYLQNJJVCMZ-UHFFFAOYSA-N](https://lmmol.com/compound/JPRXYLQNJJVCMZ-UHFFFAOYSA-N)

Ingredient–compound links use FDA openFDA/GSRS identifiers and an exact lmmol InChIKey join. Ingredient names cannot create a link.

## Related pages

- [Sponsor company](/company/OGN/)
- [FDA-approved application index](/drug/)

Sources: https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files · https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files · https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA020865. FDA data retrieved 2026-08-07.

Regulatory listing data as published by FDA; not medical or investment advice.